focus -WSS

focus

author：comprehensive 2025-08-17 00:02:30 - browse：84759

Steven Pearson — ICER President Steven D. Pearson Craig F. Walker/The Boston Globe

Meetings of the Institute for Clinical and Economic Review don’t usually get one’s heart pumping. But a meeting Thursday at the Massachusetts Institute of Technology may prove to be the exception to that rule.

Patients Rising Now, an advocacy group that says it promotes transparency in health care and that is a fierce opponent of ICER’s, is expected to face off with the self-professed “watchdog of drug pricing” as it reviews three drugs for Duchenne muscular dystrophy.

Dozens of Duchenne patients and their families — many of whom also express concern that ICER’s review could undermine insurers’ already tepid interest in the treatments — are also expected to be in attendance.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Malaria cases in Florida and Texas: Here’s what you need to know
Next article： Physician assistants need a new name. Here's what it should be

focus

WSS

What is artificial intelligence? Experts weigh in

Grand jury probing Trump's efforts to overturn 2020 election did not meet Friday: Sources

FDA early review: GLP

Rune Labs, whose app tracks Parkinson's symptoms, raises $12M

New chart reveals military’s vast involvement in Operation Warp Speed

Grand jury probing Trump's efforts to overturn 2020 election did not meet Friday: Sources

hotspot

focus

focus

Alkermes shareholders re

A preacher's new calling: Diversifying neuroscience research

The cancer drug shortage isn’t new — and neither are the solutions

New chief aims to remake Sanofi Genzyme

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Hospital chaplains balance Covid safety with patients’ spiritual needs

Peter Hotez and the public health issue of online harassment

Allen Institute goes after foundational questions, CEO Costa says

Walensky prepares to leave CDC — and Congress — behind

Dispute over threat of extinction posed by artificial intelligence looms over surging industry

hotspot

American taxpayers paid $1.8 trillion in health care costs in 2022

Medicare Advantage coverage denials need scrutiny, senators say

How Brent Saunders' Allergan experiment failed

Pfizer's RSV vaccine recommended for approval in Europe

Study suggests new cause of Down syndrome: cells linked to aging

Merck to acquire Harpoon Therapeutics for $680 million

focus

hotspot

focus

hotspot